Last Updated : May 9, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort ascending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Givlaari | givosiran | Acute hepatic porphyria (AHP) in adults | Reimburse with clinical criteria and/or conditions | Complete | ||
| Giotrif | Afatinib | Advanced or Metastatic Non-Small Cell Lung Cancer | Reimburse | Complete | ||
| Gilenya | Fingolimod | Multiple Sclerosis, relapsing-remitting | List with clinical criteria and/or conditions | Complete | ||
| Genvoya | Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide | HIV infection | List | Complete | ||
| Genotropin | Somatropin | Growth hormone deficiency, adult | List with criteria/condition | Complete | ||
| Genotropin | Somatropin | Growth hormone deficiency, children | List with criteria/condition | Complete | ||
| Genotropin | Somatropin | Turner Syndrome | List with criteria/condition | Complete | ||
| Gelnique | Oxybutynin Chloride Gel | Overactive bladder | Do not list | Complete | ||
| Gazyva | Obinutuzumab | Follicular Lymphoma (previously untreated) | Do not reimburse | Complete | ||
| Gazyva | Obinutuzumab | Chronic Lymphocytic Leukemia | Reimburse | Complete |
Last Updated : May 9, 2024